QUOTED. July 27, 2018. Opher Shapira.
Israeli cancer diagnostics firm Nucleix is planning to scale up European commercial activities to expand the reach of its first product for bladder cancer, Bladder EpiCheck. See what Nucleix CEO Opher Shapira said about it here.
"The company is currently in advanced negotiations with additional leading distributors in various European countries to expand its commercial reach. We believe Bladder EpiCheck shows the best performance of bladder cancer recurrence detection compared to all other noninvasive solutions. In addition, the test is easy to adopt in any lab and is highly cost-effective." –Opher Shapira, CEO, Nucleix
Click here for a free trial of Medtech Insight